• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助化疗可消除食管癌患者术后感染并发症对生存的负面影响。

The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer.

机构信息

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.

Department of Surgery, Yokohama City University, Yokohama, Japan.

出版信息

Ann Surg Oncol. 2018 Jul;25(7):2034-2043. doi: 10.1245/s10434-018-6504-8. Epub 2018 May 10.

DOI:10.1245/s10434-018-6504-8
PMID:29748890
Abstract

BACKGROUND

This study was designed to investigate whether postoperative infectious complications (ICs) are a risk factor for the prognosis in esophageal cancer patients who receive neoadjuvant chemotherapy by stratifying the response to neoadjuvant chemotherapy.

METHODS

The present study retrospectively examined patients who received neoadjuvant chemotherapy followed by esophagectomy between January 2011 and September 2015. Risk factors for overall survival (OS) were examined by Cox proportional hazard analyses. Pathological responders to neoadjuvant chemotherapy were defined as those with a tumor disappearance of more than one-third of the initial tumor. Postoperative ICs were defined using the Clavien-Dindo classification.

RESULTS

Of the 111 patients examined, 45 (40.5%) developed postoperative ICs. A pathological response to neoadjuvant chemotherapy was observed in 54 (48.6%) patients. The multivariate analysis demonstrated that postoperative ICs were a significant independent risk factor for the OS (hazard ratio [HR] 2.359; 95% confidence interval [CI] 1.057-5.263, p = 0.036). In the subset analysis, postoperative ICs were a marginally significant independent risk factor for OS in the nonresponders (HR 2.862; 95% CI 0.942-8.696, p = 0.063) but not in the responders (HR 0.867; 95% CI 0.122-6.153, p = 0.886).

CONCLUSIONS

These results suggested that the negative survival impact of postoperative ICs can be canceled out in esophageal cancer patients who respond to neoadjuvant chemotherapy.

摘要

背景

本研究旨在通过分层新辅助化疗的反应,探讨术后感染性并发症(ICs)是否是接受新辅助化疗后食管癌患者预后的危险因素。

方法

本研究回顾性分析了 2011 年 1 月至 2015 年 9 月期间接受新辅助化疗后行食管切除术的患者。采用 Cox 比例风险分析检查总生存率(OS)的危险因素。新辅助化疗的病理反应定义为初始肿瘤的三分之一以上消失的肿瘤。术后 ICs 采用 Clavien-Dindo 分类定义。

结果

在检查的 111 例患者中,45 例(40.5%)发生术后 ICs。54 例(48.6%)患者对新辅助化疗有病理反应。多因素分析表明,术后 ICs 是 OS 的显著独立危险因素(危险比 [HR] 2.359;95%置信区间 [CI] 1.057-5.263,p=0.036)。在亚组分析中,术后 ICs 是无反应者 OS 的独立危险因素(HR 2.862;95%CI 0.942-8.696,p=0.063),但不是有反应者的 OS 的独立危险因素(HR 0.867;95%CI 0.122-6.153,p=0.886)。

结论

这些结果表明,在对新辅助化疗有反应的食管癌患者中,术后 ICs 的负面生存影响可以消除。

相似文献

1
The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer.新辅助化疗可消除食管癌患者术后感染并发症对生存的负面影响。
Ann Surg Oncol. 2018 Jul;25(7):2034-2043. doi: 10.1245/s10434-018-6504-8. Epub 2018 May 10.
2
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?新辅助放化疗与手术治疗食管鳞癌的时间间隔:手术延迟是否影响预后?
Ann Surg Oncol. 2013 Dec;20(13):4245-51. doi: 10.1245/s10434-013-3139-7.
3
Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy.新辅助化疗后食管癌鳞状细胞癌淋巴结清扫的治疗价值
J Surg Oncol. 2015 Jul;112(1):60-5. doi: 10.1002/jso.23965. Epub 2015 Jul 14.
4
The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.新辅助化疗治疗食管鳞癌患者的肿瘤病理性缓解和淋巴结状态对生存和全身疾病的影响。
Ann Surg Oncol. 2018 Aug;25(8):2409-2417. doi: 10.1245/s10434-018-6507-5. Epub 2018 May 10.
5
Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.扩大CROSS新辅助放化疗原入选标准对食管癌毒性和生存的影响
Ann Surg Oncol. 2017 Jul;24(7):1811-1820. doi: 10.1245/s10434-017-5797-3. Epub 2017 Feb 10.
6
Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.新辅助和辅助治疗与单纯手术治疗可切除食管癌的生存率比较:一项网状Meta分析。
Ann Surg. 2017 Mar;265(3):481-491. doi: 10.1097/SLA.0000000000001905.
7
Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.前瞻性新辅助治疗及手术后,病理T0(ypT0)食管鳞状细胞癌中残留淋巴结转移的肿瘤学结局
Ann Surg Oncol. 2015;22(6):1851-7. doi: 10.1245/s10434-014-4195-3. Epub 2014 Oct 25.
8
Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.新辅助放化疗期间骨骼肌质量的丧失可预测食管癌手术的术后死亡率。
Ann Surg Oncol. 2015 Dec;22(13):4445-52. doi: 10.1245/s10434-015-4558-4. Epub 2015 Apr 17.
9
Clinical Outcome of Esophagectomy in Elderly Patients With and Without Neoadjuvant Therapy for Thoracic Esophageal Cancer.老年胸段食管癌患者接受与未接受新辅助治疗的食管切除术后的临床结局
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S794-801. doi: 10.1245/s10434-015-4769-8. Epub 2015 Jul 30.
10
Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.新辅助治疗对食管鳞癌患者术后并发症不良长期结局的影响:一项回顾性队列研究。
Ann Surg Oncol. 2019 Jul;26(7):2081-2089. doi: 10.1245/s10434-019-07312-z. Epub 2019 Apr 1.

引用本文的文献

1
The Risk of Infection-Caused Mortality in Gastric Adenocarcinoma: A Population-Based Study.胃腺癌感染所致死亡风险:一项基于人群的研究。
Gastroenterology Res. 2024 Jun;17(3):133-145. doi: 10.14740/gr1715. Epub 2024 Jun 29.
2
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.食管癌免疫治疗的最新综述:程序性死亡配体1印记
Cent Eur J Immunol. 2024;49(1):77-90. doi: 10.5114/ceji.2024.139269. Epub 2024 May 9.
3
Prognostic Impact of Post-operative Infectious Complications in Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy: Post Hoc Analysis of a Randomized Controlled Trial, JCOG0501.
新辅助化疗胃癌患者术后感染并发症的预后影响:JCOG0501 随机对照试验的事后分析。
J Gastrointest Cancer. 2024 Sep;55(3):1125-1133. doi: 10.1007/s12029-024-01061-3. Epub 2024 May 4.
4
Survival impact of surgical site infection in esophageal cancer surgery: A multicenter retrospective cohort study.食管癌手术中手术部位感染对生存的影响:一项多中心回顾性队列研究。
Ann Gastroenterol Surg. 2023 Jan 18;7(4):603-614. doi: 10.1002/ags3.12656. eCollection 2023 Jul.
5
Risk Factors for Postoperative Anastomosis Leak After Esophagectomy for Esophageal Cancer.食管癌根治术后吻合口瘘的危险因素。
In Vivo. 2020 Mar-Apr;34(2):857-862. doi: 10.21873/invivo.11849.
6
Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care.食管癌手术围手术期应用类固醇治疗及术后加强康复护理后,术后C反应蛋白水平是一个预后指标。
In Vivo. 2019 Mar-Apr;33(2):587-594. doi: 10.21873/invivo.11515.